共查询到10条相似文献,搜索用时 187 毫秒
1.
Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus 总被引:32,自引:0,他引:32
Zhou J Tang ZY Fan J Wu ZQ Li XM Liu YK Liu F Sun HC Ye SL 《Journal of cancer research and clinical oncology》2000,126(1):57-61
Purpose: Both platelet-derived endothelial cell growth factor (PD-ECGF) and vascular endothelial growth factor (VEGF) are known to
promote the development of new blood vessels, which are fundamental to tumor growth and metastasis. We aimed at evaluating
the gene expression of PD-ECGF and VEGF in hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). Patients and methods: Surgical specimens (28 HCC, 28 nontumorous liver tissues and 18 PVTT) were studied by Northern blot analysis. The levels
of PD-ECGF mRNA and VEGF mRNA expression were measured by densitometric scanning of the autoradiographs, and they were normalized
to the level of expression of an internal control (glyceraldehyde-phosphate dehydrogenase) mRNA. Results: The expression rates of PD-ECGF mRNA in PVTT, HCC and nontumorous liver tissues were 77.8% (14/18), 67.9% (19/28) and 35.7%
(10/28), being 88.9% (16/18), 75.0% (21/28) and 17.9% (5/28) respectively for VEGF mRNA. The expressions of PD-ECGF mRNA and
VEGF mRNA were higher in HCC with PVTT than when PVTT was absent (P < 0.05). The PVTT was more often seen in patients with positive expression of both PD-ECGF mRNA and VEGF mRNA in HCC than
in patients who were positive for only one of these factors or negative for both (P < 0.05). Conclusion: Both PD-ECGF and VEGF correlated well with the formation of PVTT of HCC.
Received: 20 June 1999 / Accepted: 20 July 1999 相似文献
2.
Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma 总被引:5,自引:0,他引:5
Ullrich Graeven Niko Andre Eike Achilles Carsten Zornig Wolff Schmiegel 《Journal of cancer research and clinical oncology》1999,125(10):577-581
Purpose: Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) have been suggested to be important mediators
for tumor-induced angiogenesis. We measured serum VEGF and bFGF levels from patients with soft-tissue sarcomas and correlated
serum VEGF and bFGF levels with tumor status at surgery and histological grading. Materials and methods: A group of 18 healthy controls and 85 patients with soft-tissue sarcoma were enrolled in this study. The patients were classified
according to tumor status at surgery. Serum levels of VEGF and bFGF were also correlated with histological grading. VEGF and
bFGF levels were determined by enzyme-linked immunosorbent assay (Quantikine R&D Systems). Results: Serum VEGF and bFGF levels were significantly elevated in the patient group (VEGF: 580pg/ml, bFbF: 21pg/ml, P = 0.0001). The highest concentrations of serum VEGF and bFGF were found in patients with macroscopic tumor lesions or G3
histology. Serum VEGF levels showed a statistically significant correlation with tumor status and grading (P = 0.006 for tumor status, P = 0.0001 for grading). Conclusions: This study reveals that elevated preoperative serum VEGF and bFGF levels can be detected in the majority of patients with
soft-tissue sarcoma. The significant correlation with tumor mass and histological grading suggests that a consecutive monitoring
of VEGF and bFGF in the serum of patients with soft-tissue sarcoma might be a valuable marker for tumor follow-up.
Received: 26 April 1999 / Accepted: 17 May 1999 相似文献
3.
Invasion and metastasis of liver cancer: expression of intercellular adhesion molecule 1 总被引:20,自引:0,他引:20
Sun JJ Zhou XD Liu YK Tang ZY Feng JX Zhou G Xue Q Chen J 《Journal of cancer research and clinical oncology》1999,125(1):28-34
To study the relationship between intercellular adhesion molecule 1 (ICAM-1) and liver cancer metastasis and to find predicting
factors that could indicate the growth and metastasis of liver cancer. Methods: ICAM-1 expression in fresh tissue of normal liver and hepatocellular cancer (HCC) was examined by immunoperoxidase staining.
Serum soluble intercellular adhesion molecule 1 (sICAM-1) from patients with a benign HCC tumor, and the expression of ICAM-1
in the orthotopically transplanted LCI-D20 tumor of a nude mouse liver cancer metastasis model, and in human hepatoma, the
tumor surrounding tissue and normal liver, was analyzed semiquantitatively by the immuno-dot blot method. Tissue ICAM-1 expression
(mRNA level) was detected by Northern blotting. Results: ICAM-1 expression in LD1-20 D metastatic liver cancer had a positive correlation with tumor size and the time after implantation.
It increased suddenly as metastasis occurred being 3.03 ± 0.51 before metastasis and 8.24 ± 0.95 after metastasis, P < 0.01, then remained high, appending on the number of sites involved (monosite metastasis 5.48 ± 0.49, multisite metastasis
10.05 ± 1.17, P < 0.05). All six cases of normal liver samples were negative in anti-ICAM-1 immunohistochemical staining, 80.0% (36/45) of
the HCC showed some ICAM-1 expression. The rate of positive cells was a little higher in large tumors, tumors with an intact
capsule and tumors with metastasis, but there was no significant difference. It was noticed that two cancer emboli also had
high ICAM-1 expression. The ICAM-1 concentration in HCC (13.43 ± 0.09) was higher than that in tumor surrounding the liver
(5.89 ± 0.17, P < 0.01) and that in normal liver (4.27 ± 0.21, P < 0.01). sICAM-1, like tissue ICAM-1, was higher in HCC patients than in patients (with benign liver tumor and normal controls.
Both tissue ICAM-1 and sICAM-1 were higher in the metastasis group than in the group without metastasis (tissue ICAM-1 20.24 ± 0.30
vs 10.23 ± 0.12 P < 0.05; sICAM-1 12.18 ± 0.25 vs 9.77 ± 0.54 P < 0.05). Northern blot analysis revealed that ICAM-1 expression, as indicated by mRNA level, was also higher in HCC and in
cancer emboli than in tumor surrounding liver and normal liver. Conclusions: Tissue ICAM-1 and serum sICAM-1 could indicate the stage of HCC, and the potential of hepatoma cells for invasion and metastasis.
They may play an important role in the metastasis cascade.
Received: 20 January 1998 / Accepted: 25 June 1998 相似文献
4.
Inhibitory effects of synthetic β peptide on invasion and metastasis of liver cancer 总被引:8,自引:0,他引:8
Sun JJ Zhou XD Liu YK Tang ZY Sun RX Zhao Y Uemura T 《Journal of cancer research and clinical oncology》2000,126(10):595-600
Purpose: To study the inhibitory effects of synthetic β peptide on invasion and metastasis of liver cancer. Methods: Membrane-type intercellular adhesion molecule-1 (ICAM-1) expression of SMMC-7721 cultured hepatoma cells (7721 cells) was
detected by immunofluorescence cell flowmeter. The adhesion of 7721 cells to fibronectin (FN) was assayed by the MTT method.
The adhesion of 7721 cells to 7721 cells, 7721 cells to endothelial cells, and 7721 cells to lymphocyte cells was detected
by adhesion assay. LCI-D20 human liver cancer metastasis model in nude mice was used in this experiment. One hundred micrograms
of β peptide per mouse were injected subcutaneously after tumor was resected premetastatically or postmetastatically to observe
its effect on liver cancer metastasis after hepatectomy. Results: Membrane-type ICAM-1 expression of SMMC-7721 cells treated by β peptide was lower than that of the untreated cells. The adhesion
of 7721 cells to FN, 7721 cells to 7721 cells, 7721 cells to endothelial cells, and 7721 cells to lymphocyte cells was also
lower in the β peptide group than in the untreated group. Conclusions:β Peptide can block the adhesion of 7721 cells to FN, 7721 cells to some host cells in vitro, and inhibit HCC metastasis of
LCI-D20 model posthepatectomy in vivo, so it could potentially act as an anti-metastasis drug.
Received: 23 November 1999 / Accepted: 10 March 2000 相似文献
5.
Hui-Chuan Sun Zhao-You Tang Xiao-Ming Li Yan-Nan Zhou Bao-Rong Sun Zeng-Chen Ma 《Journal of cancer research and clinical oncology》1999,125(7):419-426
Purpose: To elucidate the relationship between angiogenesis and prognosis after curative resection of hepatocellular carcinoma (HCC).
Methods: An immunohistochemical study using anti-CD34 monoclonal antibody was carried out on surgical specimens from 78 HCC patients
who had undergone curative resection; microvessel density (MVD) was counted and the overall survival and disease-free survival
were analyzed retrospectively. Results: Blood vessels in the tumor were strongly stained by anti-CD34 antibody, but not those in the surrounding liver parenchyma.
There were three types of tumor vessels: capillary-like (n = 59), sinusoid-like (n = 16) and mixed-type (n = 3). The median MVD count was 100 per field. The HCC were designated as hypovascular (n = 36) with an MVD count below 100, and hypervascular (n = 42) with an MVD count of 100 or more per field. The 5-year survival and disease-free survival rates were 49.7% and 42.8%
respectively, and statistical analysis showed that the MVD level was not correlated with tumor size, capsule status, Edmondson's
grade, α-fetoprotein level, associated cirrhosis, γ-glutamyltransferase, and serum HBsAg status. The sinusoid-like tumor vessels
appeared more frequently in the more differentiated tumors (P < 0.05). No statistical difference in overall and disease-free survival between different MVD levels and microvessel types
was found. Tumor size was the only predicting factor in the entire series. In patients with small HCC (≤ 5 cm, n = 40), 5-year survival and disease-free survival rates were 58.9% and 52.7% respectively, higher than the values in large
HCC (39.8% and 32.0% respectively, P < 0.05). The MVD level was an independent predicting factor of disease-free survival, 5-year disease-free survival in the
hypovascular group (74.6%) being better than that in the hypervascular group (34.7%, P < 0.05). Conclusions: The MVD level was not related to tumor size, capsule statuo, Edmondson's grade, α-fetoprotein level, associated cirrhosis,
γ-glutamyltransferase and serum HBsAg status. In the entire series, tumor size was the only factor influencing survival after
curative resection. However, in patients with small HCC, the MVD level was an independent factor of disease-free survival.
The pathological and clinical implications of different types of tumor vessels in HCC remain to be studied.
Received: 27 November 1998 / Accepted: 5 January 1999 相似文献
6.
Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor 总被引:4,自引:0,他引:4
Jean-Marc Schlaeppi Gerhard Siemeister Karin Weindel Christian Schnell Jeanette Wood 《Journal of cancer research and clinical oncology》1999,125(6):336-342
Vascular endothelial growth factor (VEGF) is an important mediator of tumor-induced angiogenesis and represents a potential
target for anticancer therapy. Therefore, we prepared a panel of monoclonal antibodies (mAb) against both the VEGF121 and VEGF165 isoforms. Three of them completely neutralized the mitogenic stimulation by VEGF of human umbilical vein endothelial cells
at mAb concentrations below 0.1 μg/ml. The most potent one, with a dissociation constant (K
d) of 8 pM, inhibited, in a dose-dependent manner, VEGF-induced angiogenesis in a growth factor implant model in mice. A complete
inhibition of the angiogenic response was obtained by daily intraperitoneal injections of 10 μg mAb/mouse. Angiogenesis induced
by basic fibroblast growth factor was not inhibited by the mAb. Epitope mapping of the mAb, performed by competitive enzyme-linked
immunosorbent assay and Western blot analysis, showed that it did not bind to the reduced and denatured monomer of VEGF. Substitutions
of three residues (Q87R, G88K, Q89K), located on the major surface loop β5 to β6 of VEGF, resulted in the complete loss of
binding (more than 400-fold reduction). The results suggest that the mAb binds primarily to a conformation-dependent epitope
on the VEGF dimeric form, encompassing one of the loop regions involved in KDR receptor binding. The mAb with its strong neutralizing
properties represents a useful agent for effective blocking of VEGF-mediated tumor neovascularization.
Received: 11 November 1998 / Accepted: 16 December 1998 相似文献
7.
Berberine inhibits angiogenic potential of Hep G2 cell line through VEGF down-regulation in vitro 总被引:1,自引:0,他引:1
Jie S Li H Tian Y Guo D Zhu J Gao S Jiang L 《Journal of gastroenterology and hepatology》2011,26(1):179-185
Background and Aim: Berberine, an herbal alkaloid, has been reported to have promotion potential of apoptosis and anticancer effect on a variety of human tumor cells. To obtain more specific understanding of those consequences of berberine on hepatocellular carcinoma (HCC) and the tumor microenvironment, we conducted in vitro experiments to investigate the inhibitory effect of berberine on tumor‐induced angiogenesis using HCC cells and human umbilical vein endothelial cells (HUVECs). Methods: Human umbilical vein endothelial cell growth was quantified with the CCK‐8 cell proliferation assay; cell migration was observed with a Boyden chamber (Transwell, Corning, Lowell, MA, USA), and angiogenesis was assessed by endothelial tube formation in Matrigel in vitro. In addition, VEGF level was determined by ELISA and VEGF mRNA expression by RT‐PCR. Results: Berberine inhibited the capacity of HCC to stimulate HUVEC's proliferation, migration and endothelial tube formation, suggesting that berberine could influence the cross‐talk between the HCC cell and vascular endothelial cells. These results demonstrate berberine's antiangiogenesis property and its clinical potential as an inhibitor of tumor angiogenesis. Subsequently analyses reveal that berberine prevents secretion of VEGF from HCC and down‐regulates VEGF mRNA expression. Conclusion: These findings strongly suggest that berberine is a potential antiangiogenic agent and a promising antitumor drug for HCC. 相似文献
8.
《Hematology (Amsterdam, Netherlands)》2013,18(1):16-21
Abstract Introduction: Bone marrow function and the growth of hemopoietic cells depends on an intact microvasculature. A pivotal regulator of angiogenesis is vascular endothelial growth factor (VEGF). Our study assesses VEGF expression and microvessel density (MVD) in the bone marrow of patients with aplastic anemia (AA). Materials and method: Bone marrow specimens from 25 patients with AA and 15 controls were studied. MVD was calculated on sections stained immunohistochemically for CD34. Subsequently, all the cases were studied for VEGF expression. Results: Bone marrow MVD in patients with AA was significantly lower than that in controls (p<0·01). There was a significant MVD difference between severe AA and moderate AA (p<0·05). VEGF expression was also significantly lower in AA cases compared to controls (p<0·05). Conclusion: Our data show that AA is associated with reduced angiogenesis and reduced VEGF expression. Defective angiogenesis may result in or aggravate bone marrow aplasia in AA patients. There are limited studies on this aspect. More studies to confirm the present hypothesis might pave the way for new treatment options in AA. 相似文献
9.
Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma 总被引:7,自引:0,他引:7
Guo RP Zhong C Shi M Zhang CQ Wei W Zhang YQ Li JQ 《Journal of cancer research and clinical oncology》2006,132(9):547-555
Purpose Whereas some studies have indicated that the prognosis of hepatocellular carcinoma (HCC) was correlated to some apoptosis and angiogenesis factors: p53, survivin, matrix metalloproteinases (MMPs, including MMP-2 and MMP-9) and vascular endothelial growth factor (VEGF), other studies have failed to confirm this. The aim of the present study is to investigate the expression of p53, survivin, MMPs and VEGF in HCC and the relationship between these factors and the prognosis of HCC patients.Methods The expression of p53, survivin, MMP-2, MMP-9 and VEGF was measured by immunohistochemical assays in the liver resection specimens of 90 patients with HCC.Results The positive rate of p53, survivin, MMP-2, MMP-9 and VEGF was 33.3, 51.1, 60.0, 37.8 and 76.7%, respectively. The expression of MMP-2, MMP-9 and VEGF was correlated to the recurrence of HCC patients, respectively (P < 0.01). No correlation was found between the expression of apoptosis factors (p53 and survivin) and the recurrence of HCC patients, respectively (P > 0.05). The positive correlations were found between MMP-2 and VEGF (r = 0.32, P < 0.01), MMP-9 and VEGF (r = 0.24, P < 0.05). Significant differences of disease-free survival rates occurred among subgroups according to the expression of MMP-2, MMP-9 and VEGF (P < 0.01). Multivariate analysis revealed that macroscopically disseminated nodules, tumor micrometastasis, high serum alpha-fetoprotein level, positive expression of MMP-9 and VEGF were independent recurrence risk factors.Conclusions Our investigation revealed that p53 and survivin could not estimate the prognosis of HCC patients. Angiogenesis factors (MMPs and VEGF) positively correlated to the prognosis of HCC patients. The expression of MMPs and VEGF in HCC tissues could be regarded as a valuable indicator in estimating the prognosis of HCC patients. 相似文献
10.
Kosuke Kaji Hitoshi Yoshiji Mitsuteru Kitade Yasuhide Ikenaka Ryuichi Noguchi Yusaku Shirai Junichi Yoshii Koji Yanase Tadashi Namisaki Masaharu Yamazaki Tatsuhiro Tsujimoto Hideto Kawaratani Hiroshi Fukui 《Hepatology research》2010,40(5):540-549
Aim: The renin–angiotensin–aldosterone system (RAAS) has become known as a prerequisite for tumor angiogenesis, including hepatocellular carcinoma (HCC). Although angiotensin II is known to play an important role in tumor growth and angiogenesis, the role of aldosterone (Ald) is still obscure. The aim of our current study was to elucidate the effect of eplerenone, a clinically used selective Ald blocker (SAB), on murine HCC development especially in conjunction with angiogenesis. Methods: To create an allograft model, we injected 1 × 106 of BNL‐HCC cells into the flanks of BALB/c mice. After the tumor was established, SAB was administrated at dose of 100 mg/kg per day. Results: Administration of SAB significantly suppressed HCC development along with inhibition of angiogenesis and expression of the vascular endothelial growth factor (VEGF), a potent angiogenic factor. SAB treatment resulted in a marked increase of apoptosis in the tumor, whereas tumor cell proliferation was not altered. Our in vitro study showed that SAB significantly suppressed the Ald‐induced endothelial proliferation and tubular formation through inhibition of phosphorylation of the extracellular signal‐regulated kinase 1/2. On the contrary, neither Ald nor SAB affected the proliferation of HCC cells in vitro. Conclusion: Ald plays a pivotal role in HCC development through VEGF‐mediated tumor angiogenesis, and SAB may be a potential new strategy in HCC therapy in the future. 相似文献